EUVIMEDEUVIMED entdecken
Crossref

ECHOCARDIOGRAPHIC CHARACTERISTICS OF MYOCARDIAL STATUS IN PATIENTS WITH DIFFERENT STAGES OF CHRONIC KIDNEY DISEASE AND ITS DYNAMICS IN DIALYSIS PATIENT UNDER SPIRONOLACTONE THERAPY

A Karabaeva, D Tazhdinov, G Saduakassova, I Ibragimova, N Yesenbayeva, D Koshanova, A Phaizullaeva, S Echankulov, N Jainakbayev

BULLETIN OF SURGERY OF KAZAKHSTAN · 2025

DOI: 10.35805/bsk2025iv005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BULLETIN OF SURGERY OF KAZAKHSTAN, 2025. Verfasst von A Karabaeva und 8 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The study aimed to evaluate myocardial status in patients with chronic kidney disease stages III–V and assess the effect of spironolactone in dialysis patients. Materials and Methods: A total of 46 patients with chronic kidney disease stages III–IV and 83 with stage V on maintenance hemodialysis were examined. Thirty-eight hemodialysis patients received spironolactone 25 mg/day for 6 months. Echocardiography was used to assess left ventricular dimensions, myocardial mass and relative wall thickness. Left ventricular hypertrophy was defined as left ventricular mass index ≥125 g/m² in men and ≥110 g/m² in women; relative wall thickness ≥0.45 was considered increased.

Results

In spironolactone-treated patients (Group 1), left atrial diameter decreased from 4.58 ± 0.11 cm to 4.40 ± 0.11 cm; end-diastolic diameter from 4.15 ± 0.13 cm to 3.94 ± 0.17 cm; posterior wall thickness from 1.29 ± 0.03 cm to 1.23 ± 0.04 cm; Left ventricular myocardial mass from 238.46 ± 19.11 g to 206.18 ± 21.45 g; and Left ventricular mass index from 132.2 ± 10.81 g/m² to 113.32 ± 11.75 g/m². In untreated patients (Group 2), parameters showed minimal change: left atrial diameter 4.03 ± 0.11 cm to 3.90 ± 0.09 cm; Left ventricular myocardial mass 293.39 ± 17.13 g to 291.52 ± 15.43 g; Left ventricular mass index 173.57 ± 10.47 g/m² to 176.94 ± 10.06 g/m².

Conclusion

In anuric hemodialysis patients, spironolactone 25 mg/day significantly reduced left ventricular posterior wall thickness, myocardial mass and volume, and left atrial size, indicating a cardioprotective effect.

Zitieren

APA

Karabaeva, A., Tazhdinov, D., Saduakassova, G., Ibragimova, I., Yesenbayeva, N., Koshanova, D., Phaizullaeva, A., Echankulov, S., & Jainakbayev, N. (2025). ECHOCARDIOGRAPHIC CHARACTERISTICS OF MYOCARDIAL STATUS IN PATIENTS WITH DIFFERENT STAGES OF CHRONIC KIDNEY DISEASE AND ITS DYNAMICS IN DIALYSIS PATIENT UNDER SPIRONOLACTONE THERAPY. BULLETIN OF SURGERY OF KAZAKHSTAN. https://doi.org/10.35805/bsk2025iv005

Vancouver

Karabaeva A, Tazhdinov D, Saduakassova G, Ibragimova I, Yesenbayeva N, Koshanova D, et al. ECHOCARDIOGRAPHIC CHARACTERISTICS OF MYOCARDIAL STATUS IN PATIENTS WITH DIFFERENT STAGES OF CHRONIC KIDNEY DISEASE AND ITS DYNAMICS IN DIALYSIS PATIENT UNDER SPIRONOLACTONE THERAPY. BULLETIN OF SURGERY OF KAZAKHSTAN. 2025. doi:10.35805/bsk2025iv005

BibTeX
@article{Karabaeva2025,
  author = {Karabaeva, A and Tazhdinov, D and Saduakassova, G and Ibragimova, I and Yesenbayeva, N and Koshanova, D and Phaizullaeva, A and Echankulov, S and Jainakbayev, N},
  title = {ECHOCARDIOGRAPHIC CHARACTERISTICS OF MYOCARDIAL STATUS IN PATIENTS WITH DIFFERENT STAGES OF CHRONIC KIDNEY DISEASE AND ITS DYNAMICS IN DIALYSIS PATIENT UNDER SPIRONOLACTONE THERAPY},
  journal = {BULLETIN OF SURGERY OF KAZAKHSTAN},
  year = {2025},
  doi = {10.35805/bsk2025iv005}
}
Kostenlos starten →